載入...

Treatment options after sorafenib failure in patients with hepatocellular carcinoma

Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because of the modest net benefit sorafenib has contributed, and rising incidence of hepatocellul...

全面介紹

Na minha lista:
書目詳細資料
發表在:Clin Mol Hepatol
Main Authors: Dika, Imane El, Abou-Alfa, Ghassan K.
格式: Artigo
語言:Inglês
出版: The Korean Association for the Study of the Liver 2017
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5760005/
https://ncbi.nlm.nih.gov/pubmed/29151326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2017.0108
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!